News >

Metastasis-Directed Therapy Shows Promise in Oligorecurrent Prostate Cancer

Jason Harris
Published: Thursday, Jan 11, 2018

Piet Ost, MD, PhD

Piet Ost, MD, PhD
For patients with oligorecurrent prostate cancer, androgen deprivation therapy (ADT)–free survival was superior for those assigned to metastasis-directed therapy (MDT) versus surveillance, according to findings from a phase II trial published in the Journal of Clinical Oncology.

Following sPLND, investigators observed hypoesthesia of the genitofemoral nerve (n = 1), lymphorrhea (n = 1), and scrotal and penile edema (n = 1).
Ost P, Decaestecker K Fonteyne V, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial [published online December 14, 2017]. J Clin Oncol. doi: 10.1200/JCO.2017.75.4853.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication